secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002290
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance updates pipeline: BLA under review, NSCLC trial on hold
---------------------------------------------------------------

- BLA for lifileucel in advanced melanoma under FDA review; pre-license inspection of iCTC facility completed in 2023.
- Clinical hold placed on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused, prior patients continue monitoring.
- Phase 2 C-144-01 pooled melanoma data: ORR 31.4%, median DOR not reached, 41.7% of responses lasting ≥24 months.
- Phase 3 TILVANCE-301 frontline melanoma trial first patient randomized in 2Q23; dual primary endpoints ORR and PFS.
- Cash $428M as of Sep 30, 2023; Proleukin acquisition for £167.7M upfront closed May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924002290/0001104659-24-002290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924002290/tm242451d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer